The COllaboration for New TReatments of Acute Stroke (CONTRAST) consortium aims to improve the outcome of patients with a stroke. It builds on the previous and successful MR CLEAN trial. CONTRAST merges translational research and pragmatic randomized clinical trials. The consortium partners will perform five large acute stroke trials to test novel treatment strategies. This is complemented by a preclinical program, the development of a large biobank, and the identification of challenges for the organization and logistics of the acute stroke care network.
€ 14 M
funding
9
partners
About CONTRAST
In the Netherlands alone, 9000 people die each year from a stroke. Many more people survive a stroke, but have to live with consequences such as (partial) paralysis and speech impairment. In 2017, seven Dutch research institutes, one French research institute, and industrial partner Stryker, established the CONTRAST consortium. Working closely with patient organisations, the goal of this multi-stakeholder effort is to develop innovative stroke treatments. Five clinical trials and translational research will help to improve patient outcomes and decrease the burden for those who survive a stroke. Visit the CONTRAST website for more information.
Supporting the consortium organisation
CONTRAST brings together clinical and translational scientists from all academic and large clinical centers. Lygature has supported the organisation of the consortium, and its main task is program management:
- Program management. Lygature is responsible for management support at consortium level. Activities include, amongst others, planning, organizing consortium meetings, reporting, and internal communications.
* Image courtesy of Stryker Neurovascular | Image Copyright © 2015 Stryker - NV00015919.AA
Lygature together with
Project updates
-
CONTRAST continues as CONTRAST 2.0
The COllaboration for New TReatments of Acute Stroke (CONTRAST) 2.0 consortium is a continuation of CONTRAST 1.0. The goal of CONTRAST 2.0 is to improve the outcome for a large group of patients that suffered from cerebral infarction, cerebral vascular stoke or cerebral haemorrhage by also focusing on the phase before and after treatment. Read more.
-
Administration of antithrombotic drugs during catheter treatment of stroke is unsafe
Administration of antithrombotic drugs during catheter treatment of stroke patients leads to an increased risk of intracerebral hemorrhage, with no beneficial effect on recovery. The researchers, led by Erasmus MC, expect their results to change worldwide guidelines for administration of antithrombotic drugs during catheter treatment of stroke.
-
New publication
The CONTRAST MR CLEAN NO-IV trial has been published in the NEJM. The results show that intravenous alteplase prior to endovascular treatment is not superior nor non-inferior to endovascular treatment alone.